Barclays PLC Ikena Oncology, Inc. Transaction History

Barclays PLC

$353 Billion
Q1 2025

A detailed history of Barclays PLC transactions in Ikena Oncology, Inc. stock. As of the latest transaction made, Barclays PLC holds 66,177 shares of IKNA stock, worth $71,471. This represents 0.0% of its overall portfolio holdings.

Number of Shares

66,177

Previous 195,311 66.12%

Holding current value

$71,471

Previous $320,000 73.44%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$1.28 - $1.69 $165,291 - $218,236	-129,134 Reduced 66.12%	66,177 $85,000
Q3 2024 Nov 15, 2024	SELL	$1.6 - $1.85 $1,172 - $1,356	-733 Reduced 0.37%	195,311 $338,000
Q2 2024 Aug 14, 2024	SELL	$1.24 - $1.82 $962 - $1,412	-776 Reduced 0.39%	196,044 $324,000
Q1 2024 May 15, 2024	SELL	$1.27 - $2.0 $60,750 - $95,670	-47,835 Reduced 19.55%	196,820 $280,000
Q4 2023 Feb 15, 2024	BUY	$1.33 - $4.4 $50,686 - $167,684	38,110 Added 18.45%	244,655 $483,000
Q3 2023 Nov 07, 2023	BUY	$4.09 - $6.43 $17,762 - $27,925	4,343 Added 2.15%	206,545 $894,000
Q2 2023 Aug 03, 2023	BUY	$3.5 - $7.31 $14,563 - $30,416	4,161 Added 2.1%	202,202 $1.33 Million
Q1 2023 May 04, 2023	SELL	$2.62 - $4.97 $3,568 - $6,769	-1,362 Reduced 0.68%	198,041 $683,000
Q4 2022 Feb 13, 2023	SELL	$2.0 - $3.7 $3,648 - $6,748	-1,824 Reduced 0.91%	199,403 $531,000
Q3 2022 Nov 03, 2022	BUY	$3.46 - $6.0 $456 - $792	132 Added 0.07%	201,227 $714,000
Q2 2022 Aug 12, 2022	SELL	$3.23 - $7.4 $14,531 - $33,292	-4,499 Reduced 2.19%	201,095 $891,000
Q1 2022 May 16, 2022	BUY	$5.61 - $13.85 $1.15 Million - $2.85 Million	205,594 New	205,594 $1.26 Million

Others Institutions Holding IKNA

# of Institutions

Shares Held

33.9M

Call Options Held

Put Options Held

View Full List

About Ikena Oncology, Inc.

Ticker IKNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,257,500
Market Cap $39.2M
Description
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. I...

More about IKNA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account